铜绿假单胞注射液和顺铂治疗结直肠癌恶性腹腔积液的疗效对比

目的回顾性分析甘露糖敏感性血凝菌毛的铜绿假单胞菌（PA-MSHA）制剂与顺铂在治疗结直肠癌恶性腹腔积液的近期疗效和安全性。 方法回顾性分析就诊于河北医科大学第四医院的腹部B超证实为中-大量腹腔积液，且经细胞学检查为恶性腹腔积液的结直肠癌患者49例。根据治疗方案的选择分为2组，铜绿组（31人）和顺铂组（18人）。铜绿组：腹腔注射铜绿假单胞注射液10 mL×10支，第1、3、5天给药，7天一个周期，共2个周期；顺铂组：腹腔注射顺铂50 mg/m²，d1，7天为1个周期，共2个周期。两组同时期内给予mFOLFOX6方案化疗。参照WHO（1981）制定的腹腔积液治疗标准进行疗效评价；参考Karnofsky评分对患者生活质量进行评价；评估治疗过程中出现的不良反应。 结果铜绿组31例中19例患者有效，顺铂组18例患者中5例有效（χ²=5.118，P=0.024）。铜绿组31例患者中22例生活质量明显改善，顺铂组18例患者中7例患者生活质量明显改善（χ²=6.586，P=0.01）。铜绿组中有12例（38.71%）患者出现发热，顺铂组中有2例（11.11%）患者出现发热（χ²=4.25，P=0.039）；铜绿组中有1例（3.23%）腹痛患者，而顺铂组中有6例（33.33%）患者出现腹痛（χ²=8.43，P=0.004）；铜绿组未出现腹腔感染，顺铂组中有2例（11.11%）患者出现腹腔感染（χ²=3.591，P=0.058）。 结论腹腔灌注铜绿假单胞注射液在治疗结直肠癌恶性腹腔积液是一种安全、有效的治疗方案，能取得较好的近期疗效，并能改善患者生活质量，且疗效优于顺铂。

Comparative study of pseudomonas aeruginosa-mannose sensitive hemagglutinin (PA-MSHA) injection and cisplatin in the treatment of colorectal cancer malignant ascites

ObjectiveRetrospective analysis to investigate the short-term curative effect and safety of pseudomonas aeruginosa-mannosesensitive hemagglutinin (PA-MSHA) and cisplatin in the treatment of malignant ascites of colorectal cancer. MethodsA retrospective analysis was made on 49 patients with colorectal cancer whose abdominal B-mode ultrasonography proved to be moderate to large amount of peritoneal effusion and malignant ascites by cytological examination in the Fourth Hospital of Hebei Medical University. There are 31 patients in the PA-MSHA group and 18 patients in the cisplatin group. PA-MSHA: Intraperitoneally inject PA-MSHA 10 mL×10 in the first, third, and fifth day, 7 days a cycle, 2 cycles in total. Cisplatin group: Intraperitoneally inject cisplatin 50 mg/m² in the first day, 7 days a cycle, 2 cycles in total. The two groups were given mFOLFOX6 chemotherapy at the same time. The short-term efficacy was evaluated according to the WHO (1981) treatment criteria for malignant ascites. The quality of life was evaluated according to the Karnofsky score, and the adverse reactions during the treatment were evaluated. ResultsAmong 31 cases in the PA-MSHA group, 19 cases were effective. Five cases in the cisplatin group were effective among 18 cases (χ²=5.118, P=0.024). The quality of life (QOL) of 22 patients were obviously improved in the PA-MSHA group, while 7 cases in the cisplatin group (χ²=6.586, P=0.01). The rate of fever is 38.71% in the PA-MSHA group and 11.11% (χ²=4.25, P=0.039) in the cisplatin group. There was 1 case (3.23%) of abdominal pain in the PA-MSHA group, six cases (33.33%)in the cisplatin group (χ²=8.43, P=0.004). There was no abdominal infection in the PA-MSHA group, and 2 cases (11.11%) of abdominal infection in the cisplatin group (χ²=3.591, P=0.058). ConclusionIntraperitoneal infusion of PA-MSHA is a safe and effective treatment for malignant ascites of colorectal cancer. It can achieve good short-term effect and improve the quality of life of patients. The effective rate in the PA-MSHA group is significantly higher than that in the cisplatin group.